These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 32372307)
1. Integrative bioinformatics analysis reveals miR-494 and its target genes as predictive biomarkers of trastuzumab-resistant breast cancer. Hermawan A; Putri H J Egypt Natl Canc Inst; 2020 Apr; 32(1):16. PubMed ID: 32372307 [TBL] [Abstract][Full Text] [Related]
2. Exosomal miR-1246 and miR-155 as predictive and prognostic biomarkers for trastuzumab-based therapy resistance in HER2-positive breast cancer. Zhang Z; Zhang L; Yu G; Sun Z; Wang T; Tian X; Duan X; Zhang C Cancer Chemother Pharmacol; 2020 Dec; 86(6):761-772. PubMed ID: 33068176 [TBL] [Abstract][Full Text] [Related]
3. Bioinformatics-based identification of miR-542-5p as a predictive biomarker in breast cancer therapy. Zhu QN; Renaud H; Guo Y Hereditas; 2018; 155():17. PubMed ID: 29371858 [TBL] [Abstract][Full Text] [Related]
4. Involvement of the Dysregulation of miR-23b-3p, miR-195-5p, miR-656-5p, and miR-340-5p in Trastuzumab Resistance of HER2-Positive Breast Cancer Cells and System Biology Approach to Predict Their Targets Involved in Resistance. Rezaei Z; Sebzari A; Kordi-Tamandani DM; Dastjerdi K DNA Cell Biol; 2019 Feb; 38(2):184-192. PubMed ID: 30702337 [TBL] [Abstract][Full Text] [Related]
5. tRNA-Derived Fragments as Novel Predictive Biomarkers for Trastuzumab-Resistant Breast Cancer. Sun C; Yang F; Zhang Y; Chu J; Wang J; Wang Y; Zhang Y; Li J; Li Y; Fan R; Li W; Huang X; Wu H; Fu Z; Jiang Z; Yin Y Cell Physiol Biochem; 2018; 49(2):419-431. PubMed ID: 30153663 [TBL] [Abstract][Full Text] [Related]
6. Estrogen receptor 1 and progesterone receptor are distinct biomarkers and prognostic factors in estrogen receptor-positive breast cancer: Evidence from a bioinformatic analysis. Wu JR; Zhao Y; Zhou XP; Qin X Biomed Pharmacother; 2020 Jan; 121():109647. PubMed ID: 31733575 [TBL] [Abstract][Full Text] [Related]
7. A pathway-based approach for identifying biomarkers of tumor progression to trastuzumab-resistant breast cancer. Nam S; Chang HR; Jung HR; Gim Y; Kim NY; Grailhe R; Seo HR; Park HS; Balch C; Lee J; Park I; Jung SY; Jeong KC; Powis G; Liang H; Lee ES; Ro J; Kim YH Cancer Lett; 2015 Jan; 356(2 Pt B):880-90. PubMed ID: 25449779 [TBL] [Abstract][Full Text] [Related]
8. Bioinformatic identification of chemoresistance-associated microRNAs in breast cancer based on microarray data. Wang YW; Zhang W; Ma R Oncol Rep; 2018 Mar; 39(3):1003-1010. PubMed ID: 29328395 [TBL] [Abstract][Full Text] [Related]
9. Exosome-transmitted miR-567 reverses trastuzumab resistance by inhibiting ATG5 in breast cancer. Han M; Hu J; Lu P; Cao H; Yu C; Li X; Qian X; Yang X; Yang Y; Han N; Dou D; Zhang F; Ye M; Yang C; Gu Y; Dong H Cell Death Dis; 2020 Jan; 11(1):43. PubMed ID: 31969559 [TBL] [Abstract][Full Text] [Related]
10. Clinical Value of miR-101-3p and Biological Analysis of its Prospective Targets in Breast Cancer: A Study Based on The Cancer Genome Atlas (TCGA) and Bioinformatics. Li CY; Xiong DD; Huang CQ; He RQ; Liang HW; Pan DH; Wang HL; Wang YW; Zhu HW; Chen G Med Sci Monit; 2017 Apr; 23():1857-1871. PubMed ID: 28416776 [TBL] [Abstract][Full Text] [Related]
11. Bioinformatics-based interaction analysis of miR-92a-3p and key genes in tamoxifen-resistant breast cancer cells. Cun J; Yang Q Biomed Pharmacother; 2018 Nov; 107():117-128. PubMed ID: 30086458 [TBL] [Abstract][Full Text] [Related]
12. Identification of novel genes associated with a poor prognosis in pancreatic ductal adenocarcinoma via a bioinformatics analysis. Zhou J; Hui X; Mao Y; Fan L Biosci Rep; 2019 Aug; 39(8):. PubMed ID: 31311829 [TBL] [Abstract][Full Text] [Related]
13. Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancer. Palomeras S; Diaz-Lagares Á; Viñas G; Setien F; Ferreira HJ; Oliveras G; Crujeiras AB; Hernández A; Lum DH; Welm AL; Esteller M; Puig T Breast Cancer Res; 2019 Jul; 21(1):79. PubMed ID: 31277676 [TBL] [Abstract][Full Text] [Related]
14. Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial. Sonnenblick A; Brohée S; Fumagalli D; Rothé F; Vincent D; Ignatiadis M; Desmedt C; Salgado R; Sirtaine N; Loi S; Neven P; Loibl S; Denkert C; Joensuu H; Piccart M; Sotiriou C Oncotarget; 2015 Oct; 6(30):30306-16. PubMed ID: 26358523 [TBL] [Abstract][Full Text] [Related]
15. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients. De Mattos-Arruda L; Bottai G; Nuciforo PG; Di Tommaso L; Giovannetti E; Peg V; Losurdo A; Pérez-Garcia J; Masci G; Corsi F; Cortés J; Seoane J; Calin GA; Santarpia L Oncotarget; 2015 Nov; 6(35):37269-80. PubMed ID: 26452030 [TBL] [Abstract][Full Text] [Related]
16. The microRNA-141-3p/ CDK8 pathway regulates the chemosensitivity of breast cancer cells to trastuzumab. Song W; Wu S; Wu Q; Zhou L; Yu L; Zhu B; Gong X J Cell Biochem; 2019 Aug; 120(8):14095-14106. PubMed ID: 31087707 [TBL] [Abstract][Full Text] [Related]
17. Identifying the key genes and microRNAs in colorectal cancer liver metastasis by bioinformatics analysis and in vitro experiments. Oncol Rep; ; . PubMed ID: 30542696 [TBL] [Abstract][Full Text] [Related]